Topical β-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve
endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of …

AIM A crossover, randomised double blind study was undertaken in 30 healthy volunteers,
in order to compare the tolerance of 2% carteolol with and without preservative in short term …

OBJECTIVE: To compare the similarities and differences among the ocular beta-blockers.
Important considerations when comparing these agents are the differences in systemic …

Es ist das Verdienst von Professor Günter K. Krieglstein, das weltweit verwendete
Standardwerk über Glaukome von M. Bruce Shields ins Deutsche übersetzt und im Hinblick …

• A systematic quantitative and qualitative overview of published randomized clinical trials
was undertaken to assess the yield of medical treatment on the outcome of patients with …

There has been a dramatic change in the medical therapy of glaucoma during the last two
decades. Until the 1980s, miotics were the drugs of first choice for treating this disease but at …

Synopsis Carteolol is a relatively potent nonselective β-adrenoceptor antagonist with partial
agonist activity. It is used topically to reduce elevated intraocular pressure (IOP) in patients …

Carteolol, a nonselective beta-adrenergic antagonist with intrinsic sympathomimetic activity,
was compared in 1% and 2% topical solutions with 0.5% timolol in 105 patients with primary …

Glaucoma is second to cataract as a leading cause of global blindness and is the leading
cause of irreversible visual loss. By the year 2020, almost 80 million people are estimated to …

Purpose To evaluate the ocular hypotensive effect and safety of carteolol hydrochloride 1%
vs timolol maleate 0.5%. Methods One hundred seventy-six patients with ocular …